<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448071</url>
  </required_header>
  <id_info>
    <org_study_id>MTR107IL-104</org_study_id>
    <nct_id>NCT00448071</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients</brief_title>
  <official_title>A Phase II, Randomized Double Blind Placebo-Controlled, Dose Escalating Study to Determine Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meditor Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wolfson Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MTR107 effect on blood pressure throught the dialysis procedure and its ability to prevent
      Intra dialytic Hypotension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present clinical trial aims to investigate and provide a more precise characterization of
      the pharmacokinetic and pharmacodynamic profile of MTR107 in a population of ESRD patients
      predisposed to developing intradialytic hypotension. The study is also designed as a dose
      esclating study aiming to assess MTR107 safety.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <completion_date>March 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A descriptive pharmacokinetic / pharmacodynamic study. No primary end-points apply.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory Efficacy Parameters:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure> Number and type of medical interventions required for treatment of hypotension.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure> Alleviation of symptoms associated with intradialytic hypotension.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure> Efficiency of dialysis as reflected by Kt/V</measure>
  </secondary_outcome>
  <enrollment>12</enrollment>
  <condition>Hypotension</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Intra Dialytic Hypotension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTR107</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 20-75 years, inclusive.

          2. Presence of frequent bouts of hypotension defined as 3 or more intradialytic
             hypotensive events per month for the last six months prior to baseline, despite
             standard adjustments in dry weight.

          3. ECG performed up to one month before study start.

          4. Well-preserved hepatic function (within normal laboratory ranges) at study entry as
             judged by:

               -  Serum Bilirubin (Total Bilirubin (direct and indirect) 0.3-1.0 mg/dL, and Direct
                  Bilirubin 0.1-0.5 mg/dL)

               -  Serum Albumin (&gt;3.6 g/dL),

               -  Serum aminotransferases (AST (0-37 U/L) and ALT (0-40 U/L)),

               -  GGT (Gamma Glutamine Trans Peptidase)

          5. Normal coagulation status at study entry as judged by PT-INR, PTT, fibrinogen and
             platelet count.

          6. Willingness to participate in the study and adhere to the study design.

          7. Willingness to sign an informed consent form.

        Exclusion Criteria:

          1. Uncontrolled hypertension &gt;140/90 mmHg.

          2. Unstable angina.

          3. Abnormal ECG which may indicate acute disease

          4. Variable weight gains.

          5. Mental retardation.

          6. Pregnancy.

          7. Malignancy or other concomitant serious diseases.

          8. Current participation in another clinical trial involving an investigational
             drug/device, or participation in such a trial within the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeev Katzir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolfson Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shay Efrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asaf Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zeev Katzir, MD</last_name>
    <phone>972-3-5028211</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeev Katzir, MD</last_name>
      <phone>972-3-5028291</phone>
      <email>katzir@wolfson.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Zeev Katzir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asaf Harofeh Medical Center</name>
      <address>
        <city>Rishon Le Zion</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shay Efrati, MD</last_name>
      <phone>972-8-9778061</phone>
    </contact>
    <investigator>
      <last_name>Shay Efrati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2007</study_first_submitted>
  <study_first_submitted_qc>March 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2007</study_first_posted>
  <last_update_submitted>March 14, 2007</last_update_submitted>
  <last_update_submitted_qc>March 14, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2007</last_update_posted>
  <keyword>Hypotension</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Intra Dialytic Hypotension</keyword>
  <keyword>ESRD</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

